Company: CERO
Filing Date: 2025-02-07
Form Type: 424B3
Source: 0001213900-25-011071
Chunk: 157

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-02-07
Form: 424B3
Chunk 157
---
6 cell
therapy, if approved, may become a component of standard of care treatment regimens, used as a monotherapy or in combination with both
small molecule therapeutics and biologics to direct robust tumor elimination.

The Increasing Prominence of CAR-T Technology

Immunotherapy is a treatment
that harnesses the components and mechanics of the immune system to address diseases and disorders. Cellular immunotherapy is a form
of immunotherapy that focuses on modulating or enhancing the activity of different immune cells. One of the more prominent and promising
therapeutic uses of T-cells to emerge has been CAR-T cell technology.

CAR-T therapy recognizes
specific antigens that are present on the surface of tumor cells and destroys them. The concept of CAR-T builds upon the normal biology
of CTLs, whereby naturally occurring receptors serve to activate these cells when a foreign pathogen or cancerous cell is detected. Conventional
CAR-T cell therapy involves the genetic manipulation of a patient’s T cells to enable these modified cells to express a receptor
designed to bind to a specific surface antigen. To engineer these cells, a fraction of a patient’s T cells are collected from their
blood, and a viral vector containing the genetic instructions for the CAR is used to insert those genes into the genome of the T cell
through a process known as transduction. Contained in a single viral vector are the genes encoding for each component of the CAR. Typical
CAR-T cells include the following components:

| ● | Antigen                                                                                          
 recognition domain. At one end of the CAR is a binding domain that is specific to a targeted     
 antigen. This domain is exposed to the outside of the engineered lymphocyte, where it can        
 recognize the target antigen or antigens. The extracellular target binding domain of CAR-T       
 therapies currently approved by the FDA typically use a single-chain variable fragment (“scFv”), 
 consisting of the heavy-chain and light-chain variable regions of an antibody.                   |

<div align='center'>87</div>

| ● | Extracellular                                                                                 
 hinge domain. The hinge domain is a small structural component which extends from the         
 outer cell membrane to the antigen recognition domain and provides conformational flexibility 
 to facilitate optimal binding of the antigen recognition domain to the targeted antigen on    
 the surface of the cancer cell.                                                               |

| ● | Transmembrane                                                                                     
 domain. This middle portion of the CAR links the antigen recognition domain to the activating     
 elements inside the cell. The transmembrane domain anchors the CAR in the